Aeras taps Chinese expertise in alliance for new TB vaccines
This article was originally published in Scrip
The US non-profit organisation Aeras and the China National Biotec Group (CNBG) have signed a definitive agreement for the joint development of new vaccines for tuberculosis, which they hope will lead to the global availability of affordable options for the prevention of the disease.
You may also be interested in...
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.